Vanguard LifeStrategy Growth Fund

The LifeStrategy Funds are a series of broadly diversified, low-cost funds with an all-index, fixed allocation approach that may provide a complete portfolio in a single fund. The four funds, each with a different allocation, target various risk-based objectives. The Growth Fund seeks to provide capital appreciation and some current income. The fund holds 80% of its assets in stocks, a portion of which is allocated to international stocks, and 20% in bonds, a portion of which is allocated to international bonds. In addition to stock market risk, the fund is also subject to currency risk and country risks. Investors with a long-term time horizon who are looking for growth of principal over time and who can accept stock market volatility may wish to consider this fund.Please note: The Lifestrategy funds are subject to the risks of their underlying funds.Effective May 12, 2026, the fund’s name will change from the Vanguard LifeStrategy Growth Fund to the Vanguard LifeStrategy 80/20 Fund. The fund's investment objective, strategies, and policies will remain unchanged.

Vanguard LifeStrategy Growth Fund trades as VASGX on NASDAQ. The company is classified in Financial Services / Asset Management and reports in USD.

The current profile places the business in Asset Management. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Detailed operating-segment data is not available for this symbol yet.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Vanguard LifeStrategy Growth Fund can be compared against peers such as American Funds Growth Portfolio F2, American Funds Growth Portfolio Class F-1, MFS International Intrinsic Value I, MFS International Intrinsic Value R6, Oakmark Fund Investor Class, T. Rowe Price Retirement 2035 Fund Advisor Class.

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $25.49B, beta of 1.12, and return on equity of N/A.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

VASGX currently shows total debt of N/A and beta of 1.12. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

Recent filings to review: 497 (2026-05-20 00:00:00), 497 (2026-05-12 00:00:00), NPORT-P (2026-03-31 00:00:00), NPORT-P (2026-03-31 00:00:00).

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://investor.vanguard.com/investment-products/mutual-funds/profile/vasgx

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.